CSF2 and neuroblastoma: Anti-GD2 monoclonal antibodies have been used in combination with various administration regimens, including chemotherapy, cytokines like IL-2 and granulocyte–macrophage colony-stimulating factor (GM-CSF), or allogeneic NK cells in neuroblastoma treatment.